CClinicalTrials.gg
Status unknownNCT05932186Updated Jul 6, 2023

Upper Trunk Block Feasibility by Anesthesia Residents

A Phase 4 interventional study of Interscalene brachial plexus block combined with general anesthesia and Upper trunk brachial plexus block combined with general anesthesia in Anesthesia, Local and Shoulder Pain, sponsored by Alexandria University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Alexandria University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study compares between the success rate of interscalene block and upper trunk block performed by anesthesia trainee for intra and postoperative analgesia during shoulder arthroscopy. The duration of performing the block, guidance intervention by the consultant and block failure will be recorded.

Read the detailed description

Investigators hypothesize that upper trunk block (UTB) is not inferior to interscalene brachial plexus block (ISB) regarding analgesia, easier to perform, with superior success rates, and less side effects in shoulder arthroscopy surgeries when undertaken by anaesthesia trainee.

A sample of 120 patients {60 patients in ISB group and 60 patients in UTB group} is needed to detect difference in 20% in rate of success of block also this sample is sufficient to detect difference in {Duration of the block performance, visualization of the anatomic structures and Consultant guidance, with a power 80% at a significance level of 05. Sample size was calculated using Number Cruncher Statistical Systems (NCSS) 2004 and Process Automation Software System (PASS) 2000 program Patients will be excluded if they have severe pulmonary disease, allergy to any of the study medications, local infection at any of the puncture sites, chronic gabapentin or pregabalin use, chronic opioid use, preexisting neuropathy of the operative limb, herniated cervical disc, or body mass index more than 35 kg/m2.

Upon arrival to the block room, the procedure will be explained to patients and a written informed consent will be obtained. Patients will be randomly categorized into two equal groups (group ISB and group UTB) using a numbered sealed envelope method. All blocks will be performed guided by a 5-13 MHz linear ultrasound (US) probe of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine.

Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. A curved array 3-5 MHz transducer of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed inferior to the costal margin in a longitudinal orientation at the anterior axillary line on the left or in the midclavicular line on the right. The ultrasound beam will be directed medially and cephalad to visualize the posterior third of the hemi-diaphragm by using either the spleen or the liver as an acoustic window, relatively. First the view will be obtained in a two-dimensional B-mode then the M-mode sonography will be used to quantify the extent of diaphragmatic excursion between full inspiration and full expiration once a view of the curved, hyperechoic diaphragmatic line has been obtained. This assessment will be carried out by the research anaesthetist.

Blocks will be carried out by anaesthesia residents who have one year experience in ultrasound guided regional anesthesia under direct supervision of a consultant anaesthetist (After demonstrating five successive blocks in each technique). Patients, surgeons, and the research anaesthetist will be blinded to the block technique.

All patients will be attached to a multichannel monitor and a venous catheter will be inserted in the dorsum of the hand of the unoperated limb. Intravenous sedation with 2 mg midazolam will be given. After tilting the extended neck to the contralateral side while the patient in the supine position, all blocks will be preceded by local anaesthetic infiltration (2-3 mL of lidocaine 1%) after applying the Standard disinfection. The local anaesthetic (LA) mixture that will be used (10 ml bupivacaine 0.25 %) in both groups.

Nerve blocks:

Group ISB:

The US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle (preferably in the upper third of the muscle to avoid injuring the dorsal scapular and long thoracic nerves) until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected. Back tracing from the supraclavicular fossa could be done instead to reach the interscalene groove.

Group UTB:

The upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.

An additional of 5 mL of the same LA mixture will be injected after performing each block superficial to the middle scalene muscle and prevertebral fascia, to block the supraclavicular nerves (lower branches of the superficial cervical plexus having C3-4 nerve roots, supplying the ''cape'' area of the shoulder) in both groups.

The duration of performing the block by the residents will be recorded, which is the time between the beginning of US scanning and needle withdrawal from the patients' neck. Inability to perform the block by residents either due to inability to specify the nerve structure correctly or to follow the needle tip during injection will be guided by the consultant and will be recorded as a guidance intervention. Guidance interventions are verbal instructions that guide the resident either to modify the image of the anatomic structures of interest by probe manipulations or to modify the needle tip path in a certain direction. Any block that will take more than 10 minutes to be performed or taken over by the consultant, will be considered a failure. Successful block performance (primary aim) is the completion of the block within 10 minutes with or without verbal guidance from the consultant.

After block performance, sensory and motor blockade will be assessed every 5min for 30min. Motor block will be evaluated by asking the patient to abduct his arm and will be graded on a three-points scale (2 = normal; 1 = weakness, and 0 = complete loss of power). Sensory block will be evaluated in the C4, C5, and C6 dermatomes and will be graded on a three-points scale (2 = normal; 1 = loss of sensation to pinprick; and 0 = loss of sensation to light touch). Block success will be defined as a sensory score of 0 within 30min.

Thirty minutes after block performance in the block room diaphragmatic excursion will be reassessed by the same research anaesthetist who did the baseline assessment before the block, as he is blinded to the block given. Complete hemi-diaphragmatic paralysis will be defined as a 75 to 100% decrease in excursion compared to baseline or the occurrence of paradoxical movement. Partial and absent hemi-diaphragmatic paresis will be defined as 25 to 75% decrease or a less than 25% decrease in diaphragmatic excursion, respectively.

Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation using intravenous propofol (1.5 to 2.0 mg/kg), rocuronium (0.6 to 0.8 mg/kg), and fentanyl (1 μg/kg). Anaesthesia will be maintained with isoflurane/air-oxygen mixture. An additional fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gm paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia.

After surgery, all patients will be transferred to the post-anaesthesia care unit (PACU) until meeting the discharge criteria. Pain at rest will be measured using an 11-point numerical rating visual analogue scale (VAS), intravenous 6 mg of nalbuphine will be given if VAS ≥4 and total nalbuphine consumption will be recorded during the postoperative hospital stay. Once oral intake is tolerated, all patients will receive multimodal analgesia consisting of oral paracetamol 1 gm every 8 hours and oral celecoxib 200mg every 12 hours.

02

Conditions studied

  • Anesthesia, Local
  • Shoulder Pain

Browse trials for

Keywords

  • Anesthesia, Local
  • Shoulder
03

In context

Shoulder Pain

707 studies on the registry are indexed under Shoulder Pain; 152 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 561 interventional studies indexed under Shoulder Pain.

Browse Shoulder Pain studies →

Lead sponsor

Alexandria University is the lead sponsor of 569 studies on the registry; 125 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Patients aged 18 to 75 years
  • American Society of Anesthesiologists physical status I to III
  • Scheduled for arthroscopic rotator cuff repair Exclusion criteria
  • Severe pulmonary disease
  • Allergy to any of the study medications
  • Local infection at any of the puncture sites
  • Chronic gabapentin or pregabalin use
  • Chronic opioid use
  • Preexisting neuropathy of the operative limb, herniated cervical disc
  • Body mass index more than 35 kg/m2.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Interscalene block

    Patients will receive inter scalene brachial plexus block combined with general anesthesia

    Procedure: Interscalene brachial plexus block combined with general anesthesia

  • Active comparator
    Upper trunk block

    Patients will receive upper trunk brachial plexus block combined with general anesthesia

    Procedure: Upper trunk brachial plexus block combined with general anesthesia

Interventions

  • ProcedureInterscalene brachial plexus block combined with general anesthesia

    Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected. Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia

  • ProcedureUpper trunk brachial plexus block combined with general anesthesia

    Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal. The following steps will be done as in the ISB group

06

What researchers measure

Primary outcomes

  1. Success rate of upper trunk block and interscalene block

    Sensory and motor blockade will be assessed 30 minutes after block performance. Motor block will be evaluated by asking the patient to abduct his arm and will be graded on a three-points scale (2 = normal; 1 = weakness, and 0 = complete loss of power). Sensory block will be evaluated in the C4, C5, and C6 dermatomes and will be graded on a three-points scale (2 = normal; 1 = loss of sensation to pinprick; and 0 = loss of sensation to light touch). Block success will be defined as a sensory score of 0 within 30min

    Time frame: 30 minutes after block performance

Secondary outcomes

  1. Duration of performing the block

    Time between the beginning of US scanning and needle withdrawal from the patients' neck

    Time frame: During the procedure

  2. Guidance interventions

    (Number of Verbal instructions that guide the resident either to modify the image of the anatomic structures of interest by probe manipulations or to modify the needle tip path in a certain direction)

    Time frame: During the procedure

  3. Visualization of anatomic structures

    5 point scale \[5-point scale according to the block given. Either the C5-6 roots or upper trunk (anterior division, posterior division, and suprascapular nerve), Very good = clearly recognizable as monofascicular or bifascicular, Good = perfectly identifiable, but presence of fascicles not clearly recognizable, Acceptable = blurry nerve structures, but good contrast between nerve roots and adjacent muscles, Poor = blurry nerve roots and muscles, Very poor = identification of nerve roots and muscles not possible\]

    Time frame: During the procedure

  4. Postoperative pain

    Pain at rest will be measured using an 11-point numerical rating visual analogue scale (VAS). 10 is the worst pain ever and 0 is no pain

    Time frame: 24 hours postoperatively

  5. Opioid consumption

    Intravenous 6 mg of nalbuphine will be given if VAS ≥4 and total nalbuphine consumption will be recorded during the postoperative hospital stay

    Time frame: 24 hours postoperatively

  6. Complications

    Number

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Alexandria Faculty of Medicine
    Alexandria, 21651, Egypt
08

References and documents

Publications

  • Abdallah FW, Halpern SH, Aoyama K, Brull R. Will the Real Benefits of Single-Shot Interscalene Block Please Stand Up? A Systematic Review and Meta-Analysis. Anesth Analg. 2015 May;120(5):1114-1129. doi: 10.1213/ANE.0000000000000688. PubMed 25822923 ↗

Individual participant data

Plan to share: Yes — Upon request

Supporting information: Study protocol, Sap

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05932186
Lead sponsor
Alexandria University
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jul 15, 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Jul 6, 2023

Study contacts

Moustafa A Moustafa, MD
Contact
moustafa.abdelaziz@alexmed.edu.eg
+201222373407
Aly MM Ahmed, MD
Contact
a_ahmed00@alexmed.edu.eg
+201224129850
Moustafa A Moustafa, MD
principal investigator · Alexandria University, Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion